CASI Pharmaceuticals Files 6-K Report
Ticker: CASIF · Form: 6-K · Filed: Apr 8, 2024 · CIK: 1962738
| Field | Detail |
|---|---|
| Company | Casi Pharmaceuticals, INC. (CASIF) |
| Form Type | 6-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, corporate-update
TL;DR
CASI Pharma filed a 6-K, standard update, nothing major to see here.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on April 8, 2024, reporting its status as a foreign private issuer. The company, previously known as CASI Pharmaceuticals Holdings, Inc. until January 18, 2023, is incorporated in E9 and has its principal executive offices in Beijing, People's Republic of China.
Why It Matters
This filing provides routine updates on the company's status and corporate information, which is important for investors tracking its regulatory compliance and corporate structure.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily contains corporate information and does not appear to disclose new material financial or operational developments.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Registrant
- CASI Pharmaceuticals Holdings, Inc. (company) — Former company name
- 001-41666 (other) — SEC File Number
- 20240408 (date) — Filing date
- 20230118 (date) — Date of name change
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company may be required to disclose or make public in its home country.
When was CASI Pharmaceuticals, Inc. formerly known as?
CASI Pharmaceuticals, Inc. was formerly known as CASI Pharmaceuticals Holdings, Inc. until January 18, 2023.
Where are CASI Pharmaceuticals, Inc.'s principal executive offices located?
The company's principal executive offices are located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
Does CASI Pharmaceuticals, Inc. file annual reports under Form 20-F or Form 40-F?
CASI Pharmaceuticals, Inc. indicates it files annual reports under Form 20-F.
What is the SEC file number for CASI Pharmaceuticals, Inc.?
The SEC file number for CASI Pharmaceuticals, Inc. is 001-41666.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 14 · Accepted 2024-04-08 07:24:44
Filing Documents
- tmb-20240408x6k.htm (6-K) — 20KB
- 0001962738-24-000014.txt ( ) — 21KB
Forward-Looking Statements
Forward-Looking Statements This 6-K contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. All information provided herein is as of the date of this 6-K, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ Wei (Larry) Zhang Name: Wei (Larry) Zhang Title: President Date: April 8, 2024